Derm Texas, Dallas, Texas, United States (Recruiting) - 01 Aug `25Roflumilast foam for facial vitiligo

Roflumilast foam for facial vitiligo

Official title: An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)

Status: Recruiting now

Description:

Derm Texas, PLLC plans to enroll about 20 participants. Roflumilast foam blocks PDE4 to reduce inflammation in the skin. Researchers hope it will calm the local immune response and help facial skin regain pigment. Topical roflumilast is sold as Zoryve for several inflammatory skin conditions; vitiligo would be a new use. Possible effects include application-site pain, headache, diarrhea, and nausea. People ages 2 to 18 may qualify. The study is recruiting at one listed site in United States.

Start date: August 01, 2025

Completion date: June 15, 2026

Organizer: Derm Texas, PLLC

Contact: Amanda Harvey, Study Coordinator

Tel.: 214 845 642 6

Email: aharvey@derm-texas.com

Link: https://clinicaltrials.gov/study/NCT07105254

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference Roflumilast foam for facial vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions